Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

2019254 citationsJournal Articlegreen Open Access

Authors

Lara E. Davis · Oregon Health & Science University

Vanessa Bolejack · Cancer Research And Biostatistics

Christopher W. Ryan · Oregon Health & Science University

Kristen N. Ganjoo · Stanford Cancer Institute

Elizabeth T. Loggers · Fred Hutch Cancer Center

Sant P. Chawla · Sarcoma Oncology Center

Mark Agulnik

Abstract

The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.

Topics & Keywords

Sarcoma Diagnosis and Treatment Colorectal Cancer Treatments and Studies Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 37, Issue 16, pp. 1424-1431

DOI: 10.1200/jco.18.02374

Field-Weighted Citation Impact: 21.71